Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells. [electronic resource]
Producer: 20120521Description: 2335-45 p. digitalISSN:- 1528-0020
- Antigens, CD34 -- metabolism
- Apoptosis -- drug effects
- Benzamides
- Blotting, Western
- Cell Nucleus -- metabolism
- Cells, Cultured
- Cyclin D1 -- metabolism
- Cytokines -- pharmacology
- Dasatinib
- Drug Synergism
- Fusion Proteins, bcr-abl -- antagonists & inhibitors
- Glycogen Synthase Kinase 3 -- antagonists & inhibitors
- Glycogen Synthase Kinase 3 beta
- Hematopoietic Stem Cells -- drug effects
- Humans
- Imatinib Mesylate
- Indoles -- pharmacology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- genetics
- Maleimides -- pharmacology
- Microscopy, Confocal
- Mitogen-Activated Protein Kinases -- metabolism
- Neoplastic Stem Cells -- drug effects
- Phosphorylation -- drug effects
- Piperazines -- pharmacology
- Protein Kinase Inhibitors -- pharmacology
- Protein Transport -- drug effects
- Proto-Oncogene Proteins pp60(c-src) -- metabolism
- Pyrimidines -- pharmacology
- Signal Transduction -- drug effects
- Thiazoles -- pharmacology
- beta Catenin -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.